Subscribe
istock-839222794-nicoelnino
NicoElnino / iStockphoto.com
8 May 2018Big Pharma

Japanese Takeda to acquire Shire for $62bn

Japanese pharmaceutical company Takeda has agreed to acquire biotech company Shire for $62 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Takeda v Zydus: FTC intervenes in sham lawsuit claims
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Big Pharma
Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition
31 October 2018   Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.
Americas
AbbVie to acquire Allergan for $63bn
25 June 2019   US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Takeda v Zydus: FTC intervenes in sham lawsuit claims
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Big Pharma
Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition
31 October 2018   Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.
Americas
AbbVie to acquire Allergan for $63bn
25 June 2019   US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.

More on this story

Americas
Takeda v Zydus: FTC intervenes in sham lawsuit claims
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Big Pharma
Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition
31 October 2018   Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.
Americas
AbbVie to acquire Allergan for $63bn
25 June 2019   US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent